Current Colorectal Cancer Reports

, Volume 10, Issue 3, pp 346–353 | Cite as

Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAF V600E Mutations in Patients with Lymph-Node-Positive Colon Cancer

  • Aziz Zaanan
  • Jean-Baptiste Bachet
  • Thierry André
  • Frank A. Sinicrope
Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Abstract

Although tumor stage remains the key determinant of colorectal cancer prognosis and treatment, there is considerable stage-independent variability in clinical outcome. Molecular markers hold promise for explaining variations in clinical behavior, and may identify patient subsets with differential efficacy and survival after adjuvant chemotherapy, which is the standard of care for patients with lymph-node-positive, i.e., stage III, colon cancer. An increased understanding of the molecular evolution and progression of colorectal cancer has identified two major pathways of tumorigenesis that are characterized by chromosomal instability and by microsatellite instability. Microsatellite instability is a consequence of deficient DNA mismatch repair that is generally due to epigenetic inactivation of MLH1 in tumors that often carry mutations (V600E) in oncogenic BRAF. Activating BRAF V600E and KRAS mutations are mutually exclusive, and in this article, we review the current status of these mutations and the mismatch repair status as prognostic biomarkers in stage III colon cancers.

Keywords

Colorectal cancer Microsatellite instability BRAF KRAS Biomarker Prognosis 

Notes

Acknowledgments

This work was supported, in part, by the French National Institute for Health and Medical Research (INSERM) (to Aziz Zaanan) and by a Senior Scientist Award (K05CA-142885 to Frank A. Sinicrope ) from the US National Cancer Institute.

Compliance with Ethics Guidelines

Conflict of Interest

Aziz Zaanan and Thierry André declare that they have no conflict of interest.

Jean-Baptiste Bachet has received support through grants from Amgen and Celgene, and has received compensation from Amgen, Merck Serono, Roche, Sanofi-Aventis, Novartis, and Lilly for service as a consultant.

Frank A. Sinicrope has received support through grants from the National Institutes of Health, Sanofi-Aventis, Imclone, Bristol-Myers Squibb, and Pfizer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75:1215–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993;260:810–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870–5.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–6.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20:1043–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005;24:3995–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.PubMedCrossRefGoogle Scholar
  15. 15.
    Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–6.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Zaanan A, Meunier K, Sangar F, et al. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications. Cell Oncol. 2011;34:155–76.CrossRefGoogle Scholar
  17. 17.
    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126:394–401.PubMedCrossRefGoogle Scholar
  19. 19.
    Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut. 2006;55:848–55.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Lanza G, Gafa R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol. 2006;24:2359–67.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2007;25:767–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–70.PubMedCrossRefGoogle Scholar
  23. 23.
    Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000;355:1745–50.PubMedCrossRefGoogle Scholar
  24. 24.
    Hemminki A, Mecklin JP, Jarvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000;119:921–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23:5635–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117:123–31.PubMedCrossRefGoogle Scholar
  29. 29.•
    Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863–75. The predictive value of MMR for the beneficial effect of 5-FU might be different according to the molecular mechanism involved in the MSI phenotype (MLH1 promoter methylation vs germline MMR gene mutation).PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.PubMedCrossRefGoogle Scholar
  32. 32.
    Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.PubMedCrossRefGoogle Scholar
  33. 33.
    Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56:4881–6.PubMedGoogle Scholar
  34. 34.
    Des Guetz G, Lecaille C, Mariani P, et al. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res. 2010;30:4297–301.PubMedGoogle Scholar
  35. 35.
    Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21:772–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol. 2010;66:659–67.PubMedCrossRefGoogle Scholar
  37. 37.
    Zaanan A, Flejou JF, Emile JF, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res. 2011;17:7470–8.PubMedCrossRefGoogle Scholar
  38. 38.••
    Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18:6531–41. A worse prognostic impact of BRAF mutation was observed in pMMR and dMMR tumors, although the effect was only significant among pMMR patients.PubMedCrossRefGoogle Scholar
  39. 39.
    Zaanan A, Bonnetain F, Sinicrope FA, et al. Colon cancer mutation: prognosis/prediction–letter. Clin Cancer Res. 2013;19:1300.PubMedCrossRefGoogle Scholar
  40. 40.
    Gavin PG, Paik S, Yothers G, Pogue-Geile KL. Colon cancer mutation: prognosis/prediction–response. Clin Cancer Res. 2013;19:1301.PubMedCrossRefGoogle Scholar
  41. 41.•
    Flejou J-F, André T, Chibaudel B, et al. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. J Clin Oncol. 2013;31(15 Suppl):3524. The beneficial effect of FOLFOX compared with 5-FU alone in terms of DFS was better in patients with dMMR tumors than in patients with pMMR tumors.Google Scholar
  42. 42.
    Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.PubMedCrossRefGoogle Scholar
  44. 44.
    Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B protocol 89803. J Clin Oncol. 2009;27:1814–21.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol. 2009;27(15 Suppl):4001.Google Scholar
  46. 46.
    Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383–93.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–33.PubMedCrossRefGoogle Scholar
  48. 48.
    Taieb J, Tabernero J, Mini E, et al. LB4. Adjuvant FOLFOX4 with or without cetuximab (CTX) in patients (PTS) with resected stage III colon cancer (CC): DFS and OS results and subgroup analyses of the PETACC8 Intergroup phase III trial. Ann Oncol. 2012;23 Suppl 9:iex9.Google Scholar
  49. 49.
    Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31:3664–72.PubMedCrossRefGoogle Scholar
  50. 50.
    Pogue-Geile K, Yothers G, Taniyama Y, et al. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst. 2013;105:989–92.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Andersen SN, Lovig T, Breivik J, et al. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol. 1997;32:62–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15:7322–9.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54:1283–6.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Cerottini JP, Caplin S, Saraga E, et al. The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg. 1998;175:198–202.PubMedCrossRefGoogle Scholar
  55. 55.
    Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002;13:1438–46.PubMedCrossRefGoogle Scholar
  56. 56.
    Inoue Y, Saigusa S, Iwata T, et al. The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep. 2012;28:1579–84.PubMedGoogle Scholar
  57. 57.
    Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998;90:675–84.PubMedCrossRefGoogle Scholar
  58. 58.
    Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85:692–6.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027–34.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Sinicrope FA, Yoon HH, Mahoney MR, et al. Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. J Clin Oncol. 2014;32(5 Suppl):3525.Google Scholar
  61. 61.
    Yoon HH, Tougeron D, Shi Q, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance). Clin Cancer Res. 2014;20:3033–43.PubMedCrossRefGoogle Scholar
  62. 62.
    Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.PubMedCrossRefGoogle Scholar
  63. 63.
    Morris VK, Overman MJ, Eng C, et al. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. J Clin Oncol. 2013;31(15 Suppl):3632.Google Scholar
  64. 64.
    De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.PubMedCrossRefGoogle Scholar
  65. 65.
    Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21:2396–402.PubMedCrossRefGoogle Scholar
  66. 66.
    Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18:890–900.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Popovici V, Budinska E, Tejpar S, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol. 2012;30:1288–95.PubMedCrossRefGoogle Scholar
  68. 68.
    Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Bond CE, Umapathy A, Buttenshaw RL, et al. Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers. PLoS One. 2012;7:e47483.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14:3408–15.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151–6.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Aziz Zaanan
    • 1
  • Jean-Baptiste Bachet
    • 2
  • Thierry André
    • 3
  • Frank A. Sinicrope
    • 1
  1. 1.Mayo Clinic and Mayo Cancer CenterRochesterUSA
  2. 2.Department of Hepato-Gastro-Enterology, Hôpital La Pitié SalpetrièreUniversité Paris VIParis Cedex 13France
  3. 3.Department of Medical Oncology, Hôpital Saint-AntoineUniversité Paris VIParis Cedex 12France

Personalised recommendations